Alison H Banham

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3926462/publications.pdf

Version: 2024-02-01

44 papers	5,000 citations	361045 20 h-index	288905 40 g-index
45 all docs	45 docs citations	45 times ranked	7401 citing authors

#	Article	IF	Citations
1	Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201. PLoS ONE, 2021, 16, e0249967.	1.1	1
2	Elevated expression of the adhesion GPCR ADGRL4/ELTD1 promotes endothelial sprouting angiogenesis without activating canonical GPCR signalling. Scientific Reports, 2021, 11, 8870.	1.6	8
3	High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations. PLoS ONE, 2020, 15, e0229743.	1.1	10
4	CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model. Frontiers in Oncology, 2020, 10, 448.	1.3	10
5	Title is missing!. , 2020, 15, e0229743.		0
6	Title is missing!. , 2020, 15, e0229743.		0
7	Title is missing!. , 2020, 15, e0229743.		0
8	Title is missing!. , 2020, 15, e0229743.		0
9	ADGRL4/ELTD1 is a highly conserved angiogenesis-associated orphan adhesion GPCR that emerged with the first vertebrates and comprises 3 evolutionary variants. BMC Evolutionary Biology, 2019, 19, 143.	3.2	7
10	Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy. Molecular Cancer Therapeutics, 2019, 18, 2030-2042.	1.9	31
11	The oncogenic roles of TRPM ion channels in cancer. Journal of Cellular Physiology, 2019, 234, 14556-14573.	2.0	18
12	ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile. Metabolites, 2019, 9, 287.	1.3	14
13	Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia. Oncotarget, 2018, 9, 3853-3866.	0.8	13
14	TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma. Histopathology, 2017, 71, 98-111.	1.6	42
15	Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy. Cancer Research, 2017, 77, 2699-2711.	0.4	27
16	Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D. Endocrinology, 2017, 158, 503-515.	1.4	17
17	DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. Pathology, 2017, 49, 731-739.	0.3	15
18	The significance of FOXP1 in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2017, 58, 1037-1051.	0.6	50

#	Article	IF	Citations
19	Therapeutic Antibodies against Intracellular Tumor Antigens. Frontiers in Immunology, 2017, 8, 1001.	2.2	90
20	Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients. Advances in Hematology, 2017, 2017, 1-9.	0.6	2
21	Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies. PLoS ONE, 2017, 12, e0176642.	1.1	7
22	The European antibody network's practical guide to finding and validating suitable antibodies for research. MAbs, 2016, 8, 27-36.	2.6	46
23	Notch signaling: its roles and therapeutic potential in hematological malignancies. Oncotarget, 2016, 7, 29804-29823.	0.8	54
24	FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures. Oncotarget, 2016, 7, 52940-52956.	0.8	16
25	Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PLoS ONE, 2015, 10, e0140483.	1.1	13
26	Pim-2 Kinase Influences Regulatory T Cell Function and Stability by Mediating Foxp3 Protein N-terminal Phosphorylation. Journal of Biological Chemistry, 2015, 290, 20211-20220.	1.6	74
27	Cancer/Testis Antigen PASD1 Silences the Circadian Clock. Molecular Cell, 2015, 58, 743-754.	4.5	51
28	Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. Experimental and Molecular Pathology, 2015, 99, 537-545.	0.9	13
29	A review of ELTD1, a pro-angiogenic adhesion GPCR. Biochemical Society Transactions, 2014, 42, 1658-1664.	1.6	25
30	The Notch ligand Jagged1 as a target for anti-tumor therapy. Frontiers in Oncology, 2014, 4, 254.	1.3	157
31	Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas. Biomarker Insights, 2014, 9, BMI.S16553.	1.0	7
32	CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma. Haematologica, 2011, 96, 78-86.	1.7	10
33	Participation of Th17 and Treg Cells in Pediatric Bronchial Asthma. Journal of Health Science, 2010, 56, 589-597.	0.9	6
34	A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immunity, 2010, 10, 8.	3.2	33
35	Cytolytic Tâ€cell response to the PASD1 cancer testis antigen in patients with diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2009, 146, 396-407.	1.2	29
36	Monoclonal antibodies raised to the human FOXP3 protein can be used effectively for detecting Foxp3+ T cells in other mammalian species. Veterinary Immunology and Immunopathology, 2009, 127, 376-381.	0.5	12

#	Article	IF	Citations
37	Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581. Expert Opinion on Therapeutic Patents, 2009, 19, 1023-1028.	2.4	1
38	Expression of theforkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the Androgen receptor in prostate cancer but is not directly regulated by Androgens or hypoxia. Prostate, 2007, 67, 1091-1098.	1.2	40
39	Cell-surface IL-7 receptor expression facilitates the purification of FOXP3+ regulatory T cells. Trends in Immunology, 2006, 27, 541-544.	2.9	116
40	FOXP3+ regulatory T cells: Current controversies and future perspectives. European Journal of Immunology, 2006, 36, 2832-2836.	1.6	120
41	B and CTL responses to the ALK protein in patients with ALK-positive ALCL. International Journal of Cancer, 2006, 118, 688-695.	2.3	58
42	Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clinical Cancer Research, 2005, 11, 1065-72.	3.2	130
43	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103, 275-282.	0.6	3,574
44	Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. Journal of Leukocyte Biology, 1999, 65, 841-845.	1.5	53